Rallybio Corporation (RLYB)
NASDAQ: RLYB · Real-Time Price · USD
7.54
+0.74 (10.88%)
At close: Feb 27, 2026, 4:00 PM EST
7.41
-0.13 (-1.76%)
After-hours: Feb 27, 2026, 7:33 PM EST
Rallybio Employees
Rallybio had 15 employees as of September 30, 2025. The number of employees decreased by 10 or -40.00% compared to the same quarter last year.
Employees
15
Change
-10
Growth
-40.00%
Revenue / Employee
$44,933
Profits / Employee
-$944,667
Market Cap
39.81M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 15 | -10 | -40.00% |
| Jun 30, 2025 | 20 | -5 | -20.00% |
| Mar 31, 2025 | 24 | -6 | -20.00% |
| Dec 31, 2024 | 25 | -18 | -41.86% |
| Sep 30, 2024 | 25 | -19 | -43.18% |
| Jun 30, 2024 | 25 | -20 | -44.44% |
| Mar 31, 2024 | 30 | -13 | -30.23% |
| Dec 31, 2023 | 43 | 2 | 4.88% |
| Sep 30, 2023 | 44 | 0 | - |
| Jun 30, 2023 | 45 | 0 | - |
| Mar 31, 2023 | 43 | 3 | 7.50% |
| Dec 31, 2022 | 41 | 6 | 17.14% |
| Sep 30, 2022 | 44 | 13 | 41.94% |
| Jun 30, 2022 | 45 | 17 | 60.71% |
| Mar 31, 2022 | 40 | 12 | 42.86% |
| Dec 31, 2021 | 35 | 7 | 25.00% |
| Sep 30, 2021 | 31 | - | - |
| Jun 30, 2021 | 28 | - | - |
| Mar 31, 2021 | 28 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Kyntra Bio | 225 |
| Passage Bio | 60 |
| Werewolf Therapeutics | 39 |
| Atara Biotherapeutics | 38 |
| Actinium Pharmaceuticals | 25 |
| Lantern Pharma | 24 |
| Tempest Therapeutics | 21 |
| ABVC BioPharma | 19 |
RLYB News
- 10 days ago - Rallybio Shares Successful Early-Stage Results for Rare Disease Drug; New Trial Set for Late 2026 - Benzinga
- 10 days ago - Rallybio Announces Positive Data for RLYB116 Phase 1 Study Demonstrating Complete and Sustained Inhibition of Terminal Complement - Business Wire
- 24 days ago - Rallybio Announces Reverse Stock Split of Common Stock - Business Wire
- 4 months ago - Rallybio Reports Third Quarter 2025 Financial Results and Provides Business Updates - Business Wire
- 5 months ago - Rallybio Completes Dosing of First Cohort in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study - Business Wire
- 6 months ago - Rallybio Receives $12.5 Million Equity Milestone Payment from Recursion for Advancement of REV102 Program - Business Wire
- 7 months ago - Rallybio Reports Second Quarter 2025 Financial Results and Provides Business Updates - Business Wire
- 8 months ago - Why Is Microcap Rallybio Stock Trading Higher On Tuesday? - Benzinga